Finnish COVID vaccine advances to clinical trial

The phase I clinical trial of the SARS-COV-2 vaccine developed by Rokote Laboratories has begun in Kuopio University Hospital. The first clinical trial will test the immunogenicity and safety of the vaccine on healthy volunteers aged 18-75.

Rokote Laboratories has been developing a SARS-COV-2 vaccine given as a nasal spray since 2020. GeneCellNano Flagship Director Seppo Ylä-Herttuala is Chairman of the Board of Rokote Laboratories, as well as the Medical Director of the clinical trial. For more information, see the press release from Rokote Laboratories.